CA3214020A1 - Novel darpin based cd70 engagers - Google Patents
Novel darpin based cd70 engagers Download PDFInfo
- Publication number
- CA3214020A1 CA3214020A1 CA3214020A CA3214020A CA3214020A1 CA 3214020 A1 CA3214020 A1 CA 3214020A1 CA 3214020 A CA3214020 A CA 3214020A CA 3214020 A CA3214020 A CA 3214020A CA 3214020 A1 CA3214020 A1 CA 3214020A1
- Authority
- CA
- Canada
- Prior art keywords
- ankyrin repeat
- protein
- binding
- binding protein
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Lock And Its Accessories (AREA)
- Ignition Installations For Internal Combustion Engines (AREA)
- Valve Device For Special Equipments (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163173186P | 2021-04-09 | 2021-04-09 | |
| US202163172973P | 2021-04-09 | 2021-04-09 | |
| US63/173,186 | 2021-04-09 | ||
| US63/172,973 | 2021-04-09 | ||
| US202163265181P | 2021-12-09 | 2021-12-09 | |
| US63/265,181 | 2021-12-09 | ||
| PCT/IB2022/053275 WO2022215032A1 (en) | 2021-04-09 | 2022-04-07 | Novel darpin based cd70 engagers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3214020A1 true CA3214020A1 (en) | 2022-10-13 |
Family
ID=81386901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3214020A Pending CA3214020A1 (en) | 2021-04-09 | 2022-04-07 | Novel darpin based cd70 engagers |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250074994A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4319883A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024513559A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230169182A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022252985A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023020685A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3214020A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023011978A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022215032A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL298168A (en) | 2020-05-14 | 2023-01-01 | Molecular Partners Ag | Multispecific proteins |
| WO2022190016A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based multi-specific t-cell engagers |
| WO2024251628A1 (en) * | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd16a binding proteins and their use |
| JP2026524079A (ja) | 2023-06-06 | 2026-07-17 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 組換えcd2結合タンパク質及びその使用 |
| WO2025181039A1 (en) | 2024-03-01 | 2025-09-04 | Molecular Partners Ag | Therapeutic combinations comprising a multi-specific t cell engager |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100150950A1 (en) * | 2006-12-14 | 2010-06-17 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
| EP3974453A3 (en) * | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| EP3514169B1 (en) * | 2010-11-26 | 2024-03-06 | Molecular Partners AG | Designed repeat proteins binding to serum albumin |
| JP2016531920A (ja) * | 2013-09-05 | 2016-10-13 | アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップAduro Biotech Holdings, Europe B.V. | Cd70結合ペプチドおよびそれに関連する方法、プロセスおよび用途 |
| US9458211B1 (en) * | 2015-04-02 | 2016-10-04 | Molecular Partners Ag | Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains |
| US11291721B2 (en) * | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| MX2020008183A (es) * | 2018-02-01 | 2020-09-22 | Pfizer | Anticuerpos especificos para cd70 y sus usos. |
| TW202010757A (zh) * | 2018-04-11 | 2020-03-16 | 美商英伊布里克斯公司 | 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途 |
| JP2022535564A (ja) * | 2019-06-04 | 2022-08-09 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 多選択性タンパク質 |
| EP3980452A1 (en) * | 2019-06-04 | 2022-04-13 | Molecular Partners AG | Recombinant 4-1bb binding proteins and their use |
| WO2022190016A1 (en) * | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based multi-specific t-cell engagers |
-
2022
- 2022-04-07 KR KR1020237036653A patent/KR20230169182A/ko active Pending
- 2022-04-07 EP EP22719030.3A patent/EP4319883A1/en active Pending
- 2022-04-07 JP JP2023561342A patent/JP2024513559A/ja active Pending
- 2022-04-07 CA CA3214020A patent/CA3214020A1/en active Pending
- 2022-04-07 US US18/554,248 patent/US20250074994A1/en active Pending
- 2022-04-07 AU AU2022252985A patent/AU2022252985A1/en not_active Abandoned
- 2022-04-07 BR BR112023020685A patent/BR112023020685A2/pt not_active Application Discontinuation
- 2022-04-07 WO PCT/IB2022/053275 patent/WO2022215032A1/en not_active Ceased
- 2022-04-07 MX MX2023011978A patent/MX2023011978A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230169182A (ko) | 2023-12-15 |
| US20250074994A1 (en) | 2025-03-06 |
| WO2022215032A1 (en) | 2022-10-13 |
| JP2024513559A (ja) | 2024-03-26 |
| EP4319883A1 (en) | 2024-02-14 |
| BR112023020685A2 (pt) | 2023-12-12 |
| MX2023011978A (es) | 2023-11-17 |
| AU2022252985A1 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240150475A1 (en) | Novel darpin based cd123 engagers | |
| US20250074994A1 (en) | Novel darpin based cd70 engagers | |
| US20240317852A1 (en) | Novel darpin based cd33 engagers | |
| TWI825086B (zh) | Her3抗原結合分子 | |
| KR20220086554A (ko) | Her3 항원-결합 분자를 사용한 암의 치료 및 예방 | |
| US20220242973A1 (en) | Recombinant fap binding proteins and their use | |
| US11834504B2 (en) | DARPin based multi-specific t-cell engagers | |
| US20240052033A1 (en) | Recombinant cd3 binding proteins and their use | |
| JP2023553697A (ja) | グリピカン-3およびt細胞受容体を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド | |
| WO2024251628A1 (en) | Recombinant cd16a binding proteins and their use | |
| EP4724473A1 (en) | Recombinant cd47 binding proteins and their use | |
| CN121263440A (zh) | 重组cd2结合蛋白及其用途 | |
| CN117242100A (zh) | 基于DARPin的新型CD70接合物 | |
| CN117255803A (zh) | 基于DARPin的新型CD33接合物 | |
| CN117177996A (zh) | 基于DARPin的新型CD123接合物 | |
| WO2025146490A1 (en) | Recombinant cd117 binding proteins and their use | |
| CN116802213A (zh) | 重组cd3结合蛋白及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250325 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250325 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250325 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260519 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260526 |